Effects of combination treatment with mood stabilizers and mirtazapine on plasma concentrations of neuroactive steroids in depressed patients

Psychoneuroendocrinology

Volumn 32, Issue 6, 2007, Pages 669-680

  Schüle, Cornelius ^a   Baghai, Thomas C ^a   di Michele, Flavia ^b   Eser, Daniela ^a   Pasini, Augusto ^b   Schwarz, Markus ^a   Rupprecht, Rainer ^a   Romeo, Elena ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Carbamazepine; Depressive disorder; Lithium; Mirtazapine; Neuroactive steroids; Neurosteroids

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 3ALPHA,5BETA TETRAHYDROPROGESTERONE; CARBAMAZEPINE; HYPERICUM PERFORATUM EXTRACT; LITHIUM; MIRTAZAPINE; MOOD STABILIZER; NEUROSTEROID; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DEPRESSION; DRUG BLOOD LEVEL; FEMALE; GAS CHROMATOGRAPHY; HAMILTON SCALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MASS SPECTROMETRY; MENTAL DISEASE; MONOTHERAPY; PRIORITY JOURNAL; STEROID BLOOD LEVEL; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LITHIUM COMPOUNDS; MALE; MIANSERIN; MIDDLE AGED; PREGNANOLONE; PROGESTERONE; STEROIDS; TRANQUILIZING AGENTS;

EID: 34347361453     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2007.04.004     Document Type: Article

References (63)

1. Baghai T.C., Di Michele F., Schule C., Eser D., Zwanzger P., Pasini A., Romeo E., and Rupprecht R. Plasma concentrations of neuroactive steroids before and after electroconvulsive therapy in major depression. Neuropsychopharmacology 30 (2005) 1181-1186
2. Ballenger J.C. The clinical use of carbamazepine in affective disorders. J. Clin. Psychiatry 49 Suppl. (1988) 13-21
3. Baulieu E.E., and Robel P. Dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEAS) as neuroactive neurosteroids. Proc. Natl. Acad. Sci. USA 95 (1998) 4089-4091
4. Belyaeva O.V., Chetyrkin S.V., Clark A.L., Kostereva N.V., Santacruz K.S., Chronwall B.M., and Kedishvili N.Y. Role of microsomal retinol/sterol dehydrogenase-like short-chain dehydrogenases/reductases in the oxidation and epimerization of 3alpha-hydroxysteroids in human tissues. Endocrinology 148 (2007) 2148-2156
5. Biggio G., Littera M., Giliberto G., Purdy R.H., and Serra M. Carbamazepine elevates plasma and brain content of neuroactive steroids. Soc. Neurosci. 24 (1998) 998
6. Cullen M., Mitchell P., Brodaty H., Boyce P., Parker G., Hickie I., and Wilhelm K. Carbamazepine for treatment-resistant melancholia. J. Clin. Psychiatry 52 (1991) 472-476
7. De la Fuente J.M., and Mendlewicz J. Carbamazepine addition in tricyclic antidepressant-resistant unipolar depression. Biol. Psychiatry 32 (1992) 369-374
8. De Montigny, C., 1994. Lithium addition in treatment-resistant depression. Int. Clin. Psychopharmacol. 9 (2) (Suppl.), 31-35.
9. Dong E., Matsumoto K., Uzunova V., Sugaya I., Takahata H., Nomura H., Watanabe H., Costa E., and Guidotti A. Brain 5alpha-dihydroprogesterone and allopregnanolone synthesis in a mouse model of protracted social isolation. Proc. Natl. Acad. Sci. USA 98 (2001) 2849-2954
10. Ebes, F., Van Lookeren-Campagne, A.M., Hartmans, H.L.A., 1998. A phase I, single center, single-blind, placebo-controlled multiple dose study of the interaction between Org 3770 and carbamazepine in healthy male volunteers no. Study 22514, Report No. NL 0003854, Oss: N.V. Organon (data on file).
11. Feiner N.F. Antiepileptic drug augmentation for treatment-resistant depression. J. Clin. Psychiatry 58 (1997) 361-363
12. Griffin L.D., and Mellon S.H. Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc. Natl. Acad. Sci. USA 96 (1999) 13512-13517
13. Guarneri P., Papadopoulos V., Pan B., and Costa E. Regulation of pregnenolone synthesis in C6-2B glioma cells by 4′-chlorodiazepam. Proc. Natl. Acad. Sci. USA 89 (1992) 5118-5122
14. Guidotti A., Dong E., Matsumoto K., Pinna G., Rasmusson A.M., and Costa E. The socially isolated mouse: a model to study the putative role of allopregnanolone and 5alpha-dihydroprogesterone in psychiatric disorders. Brain Res. Brain Res. Rev. 37 (2001) 110-115
15. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23 (1960) 56-62
16. Jaworska-Feil L., Budziszewska B., Leskiewicz M., and Lason W. Effects of some centrally active drugs on the allopregnanolone synthesis in rat brain. Pol. J. Pharmacol. 52 (2000) 359-365
17. Kahn D. Carbamazepine and other antiepileptic drugs in refractory depression. In: Roose S.P., and Glassman A.H. (Eds). Treatment Strategies for Refractory Depression (1990), American Psychiatric Press, Washington, DC 77-107
18. Kahn D.A., Sachs G.S., Printz D.J., Carpenter D., Docherty J.P., and Ross R. Medication treatment of bipolar disorder 2000: a summary of the expert consensus guidelines. J. Psychiatr. Pract. 6 (2000) 197-211
19. Ketter T.A., Frye M.A., Cora-Locatelli G., Kimbrell T.A., and Post R.M. Metabolism and excretion of mood stabilizers and new anticonvulsants. Cell. Mol. Neurobiol. 19 (1999) 511-532
20. Khisti R.T., Chopde C.T., and Jain S.P. Antidepressant-like effect of the neurosteroid 3alpha-hydroxy-5alpha-pregnan-20-one in mice forced swim test. Pharmacol. Biochem. Behav. 67 (2000) 137-143
21. Kravitz H.M., and Fawcett J. Carbamazepine in the treatment of affective disorders. Med. Sci. Res. 15 (1987) 1-8
22. Kroboth P.D., Salek F.S., Pittenger A.L., Fabian T.J., and Frye R.F. DHEA and DHEA-S: a review. J. Clin. Pharmacol. 39 (1999) 327-348
23. Lambert J.J., Belelli D., Hill-Venning C., and Peters J.A. Neurosteroids and GABAA receptor function. Trends Pharmacol. Sci. 16 (1995) 295-303
24. Le Goascogne C., Robel P., Gouezou M., Sananes N., Baulieu E.E., and Waterman M. Neurosteroids: cytochrome P-450scc in rat brain. Science 237 (1987) 1212-1215
25. Maayan R., Shaltiel G., Poyurovsky M., Ramadan E., Morad O., Nechmad A., Weizman A., and Agam G. Chronic lithium treatment affects rat brain and serum dehydroepiandrosterone (DHEA) and DHEA-sulphate (DHEA-S) levels. Int. J. Neuropsychopharmacol. 7 (2004) 71-75
26. Majewska M.D., Demirgoren S., Spivak C.E., and London E.D. The neurosteroid dehydroepiandrosterone sulfate is an allosteric antagonist of the GABAA receptor. Brain Res. 526 (1990) 143-146
27. Marangos P.J., Post R.M., Patel J., Zander K., Parma A., and Weiss S. Specific and potent interactions of carbamazepine with brain adenosine receptors. Eur. J. Pharmacol. 93 (1983) 175-182
28. Moustgaard G. Treatment-refractory depression successfully treated with the combination of mirtazapine and lithium. J. Clin. Psychopharmacol. 20 (2000) 268
29. Navarre C., Maurin C., and Colonna L. Effect of carbamazepine combined with an ineffective antidepressant. Apropos of 4 cases. Encephale 20 (1994) 79-80
30. Otani K., Yasui N., Kaneko S., Ohkubo T., Osanai T., and Sugawara K. Carbamazepine augmentation therapy in three patients with trazodone-resistant unipolar depression. Int. Clin. Psychopharmacol. 11 (1996) 55-57
31. Padberg F., Di Michele F., Zwanzger P., Romeo E., Bernardi G., Schule C., Baghai T.C., Ella R., Pasini A., and Rupprecht R. Plasma concentrations of neuroactive steroids before and after repetitive transcranial magnetic stimulation (rTMS) in major depression. Neuropsychopharmacology 27 (2002) 874-878
32. Papadopoulos V., Lecanu L., Brown R.C., Han Z., and Yao Z.X. Peripheral-type benzodiazepine receptor in neurosteroid biosynthesis, neuropathology and neurological disorders. Neuroscience 138 (2006) 749-756
33. Patsalos P.N., and Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol. 2 (2003) 347-356
34. Paul S.M., and Purdy R.H. Neuroactive steroids. FASEB J. 6 (1992) 2311-2322
35. Post, R.M., Uhde, T.W., 1983. Treatment of mood disorders with antiepileptic medications: clinical and theoretical implications. Epilepsia 24 (2) (Suppl.), S97-S108.
36. Post R.M., and Uhde T.W. Carbamazepine as a treatment of refractory depressive illness and rapidly cycling manic-depressive illness. In: Zohar J., and Belmaker R.H. (Eds). Treating Resistant Depression (1987), PMA Publishing, New York 175-235
37. Post R.M., Uhde T.W., Roy-Byrne P.P., and Joffe R.T. Antidepressant effects of carbamazepine. Am. J. Psychiatry 143 (1986) 29-34
38. Post R.M., Weiss S.R., and Chuang D.M. Mechanisms of action of anticonvulsants in affective disorders: comparisons with lithium. J. Clin. Psychopharmacol. 12 (1992) 23S-35S
39. Prasad A.J. Efficacy of carbamazepine as an antidepressant in chronic resistant depressives. J. Indian Med. Assoc. 83 (1985) 235-237
40. Romeo E., Auta J., Kozikowski A.P., Ma D., Papadopoulos V., Puia G., Costa E., and Guidotti A. 2-Aryl-3-indoleacetamides (FGIN-1): a new class of potent and specific ligands for the mitochondrial DBI receptor (MDR). J. Pharmacol. Exp. Ther. 262 (1992) 971-978
41. Romeo E., Strohle A., Spalletta G., Di Michele F., Hermann B., Holsboer F., Pasini A., and Rupprecht R. Effects of antidepressant treatment on neuroactive steroids in major depression. Am. J. Psychiatry 155 (1998) 910-913
42. Rupprecht R. Neuroactive steroids: mechanisms of action and neuropsychopharmacological properties. Psychoneuroendocrinology 28 (2003) 139-168
43. Rupprecht R., and Holsboer F. Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci. 22 (1999) 410-416
44. Rush A.J., Roffwarg H.P., Giles D.E., Schlesser M.A., Fairchild C., and Tarell J. Psychobiological predictors of antidepressant drug response. Pharmacopsychiatria 16 (1983) 192-194
45. Rybakowski J.K., Suwalska A., and Chlopocka-Wozniak M. Potentiation of antidepressants with lithium or carbamazepine in treatment-resistant depression. Neuropsychobiology 40 (1999) 134-139
46. Schule C., Di Michele F., Baghai T., Romeo E., Bernardi G., Zwanzger P., Padberg F., Pasini A., and Rupprecht R. Influence of sleep deprivation on neuroactive steroids in major depression. Neuropsychopharmacology 28 (2003) 577-581
47. Schule C., Romeo E., Uzunov D.P., Eser D., Di Michele F., Baghai T.C., Pasini A., Schwarz M., Kempter H., and Rupprecht R. Influence of mirtazapine on plasma concentrations of neuroactive steroids in major depression and on 3alpha-hydroxysteroid dehydrogenase activity. Mol. Psychiatry 11 (2006) 261-272
48. Serra M., Madau P., Chessa M.F., Caddeo M., Sanna E., Trapani G., Franco M., Liso G., Purdy R.H., Barbaccia M.L., and Biggio G. 2-Phenyl-imidazo[1,2-a]pyridine derivatives as ligands for peripheral benzodiazepine receptors: stimulation of neurosteroid synthesis and anticonflict action in rats. Br. J. Pharmacol. 127 (1999) 177-187
49. Serra M., Littera M., Pisu M.G., Muggironi M., Purdy R.H., and Biggio G. Steroidogenesis in rat brain induced by short- and long-term administration of carbamazepine. Neuropharmacology 39 (2000) 2448-2456
50. Sitsen J.M., Voortman G., and Timmer C.J. Pharmacokinetics of mirtazapine and lithium in healthy male subjects. J. Psychopharmacol. 14 (2000) 172-176
51. Sotsky S.M., Glass D.R., Shea M.T., Pilkonis P.A., Collins J.F., Elkin I., Watkins J.T., Imber S.D., Leber W.R., and Moyer J. Patient predictors of response to psychotherapy and pharmacotherapy: findings in the NIMH Treatment of Depression Collaborative Research Program. Am. J. Psychiatry 148 (1991) 997-1008
52. Stormer E., von Moltke L.L., Shader R.I., and Greenblatt D.J. Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug. Metab. Dispos. 28 (2000) 1168-1175
53. Strohle A., Romeo E., Di Michele F., Pasini A., Hermann B., Gajewsky G., Holsboer F., and Rupprecht R. Induced panic attacks shift gamma-aminobutyric acid type A receptor modulatory neuroactive steroid composition in patients with panic disorder: preliminary results. Arch. Gen. Psychiatry 60 (2003) 161-168
54. Stromgren L.S., and Boller S. Carbamazepine in treatment and prophylaxis of manic-depressive disorder. Psychiatr. Dev. 3 (1985) 349-367
55. Tateishi T., Asoh M., Nakura H., Watanabe M., Tanaka M., Kumai T., and Kobayashi S. Carbamazepine induces multiple cytochrome P450 subfamilies in rats. Chem. Biol. Interact. 117 (1999) 257-268
56. Timmer C.J., Sitsen J.M., and Delbressine L.P. Clinical pharmacokinetics of mirtazapine. Clin. Pharmacokinet. 38 (2000) 461-474
57. Trauger J.W., Jiang A., Stearns B.A., and LoGrasso P.V. Kinetics of allopregnanolone formation catalyzed by human 3 alpha-hydroxysteroid dehydrogenase type III (AKR1C2). Biochemistry 41 (2002) 13451-13459
58. Uzunov D.P., Cooper T.B., Costa E., and Guidotti A. Fluoxetine-elicited changes in brain neurosteroid content measured by negative ion mass fragmentography. Proc. Natl. Acad. Sci. USA 93 (1996) 12599-12604
59. Uzunova V., Sheline Y., Davis J.M., Rasmusson A., Uzunov D.P., Costa E., and Guidotti A. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc. Natl. Acad. Sci. USA 95 (1998) 3239-3244
60. Uzunova V., Ceci M., Kohler C., Uzunov D.P., and Wrynn A.S. Region-specific dysregulation of allopregnanolone brain content in the olfactory bulbectomized rat model of depression. Brain Res. 976 (2003) 1-8
61. Uzunova V., Wrynn A.S., Kinnunen A., Ceci M., Kohler C., and Uzunov D.P. Chronic antidepressants reverse cerebrocortical allopregnanolone decline in the olfactory-bulbectomized rat. Eur. J. Pharmacol. 486 (2004) 31-34
62. Wittchen H.U., Wunderlich U., Zaudig M., and Fydrich T. Strukturiertes Klinisches Interview für DSM-IV. Achse I: Psychische Störungen (Structured clinical interview for DSM-IV, Axis I, German version) (1997), Hogrefe, Göttingen
63. Wunderlich H.P., Grunes J.U., Neumann J., and Zahlten W. Antidepressive therapy with carbamazepine (Finlepsin). Schweiz. Arch. Neurol. Neurochir. Psychiatr. 133 (1983) 363-371